Amneal Pharmaceuticals, Inc. AMRX Affordable Medicines — R&D
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amneal Pharmaceuticals, Inc.'s affordable medicines — r&d.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s affordable medicines — R&D?
- Amneal Pharmaceuticals, Inc. (AMRX) reported affordable medicines — R&D of $33.29M in Q1 2026.
- How has Amneal Pharmaceuticals, Inc.'s affordable medicines — R&D changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s affordable medicines — R&D increased by 7.4% year-over-year, from $30.98M to $33.29M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s affordable medicines — R&D?
- Over 3 years (2022 to 2025), Amneal Pharmaceuticals, Inc.'s affordable medicines — R&D has grown at a -2.3% compound annual growth rate (CAGR), from $167.51M to $156.01M.
- What does affordable medicines — R&D mean?
- Reflects the investment in scientific research, clinical trials, and product development activities aimed at expanding the Affordable Medicines portfolio. High levels of investment indicate a commitment to long-term innovation and pipeline growth.